196 related articles for article (PubMed ID: 23674313)
1. Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Sandhu A; Seth M; Dixon S; Share D; Wohns D; Lalonde T; Moscucci M; Riba AL; Grossman M; Gurm HS
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):293-8. PubMed ID: 23674313
[TBL] [Abstract][Full Text] [Related]
2. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.
Zeymer U; James S; Berkenboom G; Mohacsi A; IƱiguez A; Coufal Z; Sartral M; Paget MA; Norrbacka K; Ferrieres J; Bakhai A;
Eur J Prev Cardiol; 2013 Apr; 20(2):218-28. PubMed ID: 22345684
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel: the real-life perspective.
Serebruany V; Atar D
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):253-4. PubMed ID: 23674315
[No Abstract] [Full Text] [Related]
4. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
Karve AM; Seth M; Sharma M; LaLonde T; Dixon S; Wohns D; Gurm HS
Am J Cardiol; 2015 Jun; 115(11):1502-6. PubMed ID: 25846767
[TBL] [Abstract][Full Text] [Related]
7. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Martin MT; Spinler SA; Nutescu EA
Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989
[TBL] [Abstract][Full Text] [Related]
8. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Angelidis C; Petousis S; Stakos D; Parissis H; Vavouranakis M; Davlouros P; Goudevenos J; Stefanadis C
Am Heart J; 2014 Jan; 167(1):68-76.e2. PubMed ID: 24332144
[TBL] [Abstract][Full Text] [Related]
9. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
Alexopoulos D; Moulias A; Koutsogiannis N; Xanthopoulou I; Kakkavas A; Mavronasiou E; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2013 Jun; 6(3):277-83. PubMed ID: 23735473
[TBL] [Abstract][Full Text] [Related]
12. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
Bagai A; Wang Y; Wang TY; Curtis JP; Gurm HS; Shah B; Cheema AN; Peterson ED; Saucedo JF; Granger CB; Roe MT; Bhatt DL; McNamara RL; Alexander KP
Circ Cardiovasc Interv; 2014 Aug; 7(4):585-93. PubMed ID: 25097196
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
14. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA
Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457
[TBL] [Abstract][Full Text] [Related]
15. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel: a critical comparison with clopidogrel.
Reinhart KM; White CM; Baker WL
Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804
[TBL] [Abstract][Full Text] [Related]
17. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
18. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
Baker WL; White CM
Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Robinson A; Das K; Koshy SK; Das P
Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]